1-3 of 3
Eduardo Cervera, MD
Close
Sort by
Journal Articles

Chronic Myeloid Leukemia Philadelphia Chromosome Positive (CML Ph+) with Imatinib (IM) Intolerance or Resistant Disease. Response to Thalidomide (TALI) Treatment. Preliminary Report of a Serial of Cases with Encouraging Results

Rafael Hurtado, MD, Jose Pablo Vargas Viveros, MD, Carrillo Muñoz Silvia, RN, Judith Cruz-Velazquez, Myrna Candelaria, MD, PhD, Eduardo Cervera, MD
Journal: Blood
Blood (2012) 120 (21): 1689.
https://doi.org/10.1182/blood.V120.21.1689.1689
Published: 2012
Journal Articles

The Age of Mexican Patients with Chronic Myeloid Leukemia (CML) Ph+ Is Quite Younger Than the Reported in USA and European Series.

Pablo Vargas-Viveros, M.D., Rafael Hurtado Monroy, MD, Eduardo Cervera, MD, Carlos Best, M.D., Alvaro Aguayo, M.D., Myrna Candelaria, MD
Journal: Blood
Blood (2009) 114 (22): 4291.
https://doi.org/10.1182/blood.V114.22.4291.4291
Published: 2009
Journal Articles

Imatinib Alone (IA) Vs. Imatinib + Ara-C (IMAC): A Randomized Phase III Clinical Trial for the Treatment of Early Phase (EP) Chronic Myeloid Leukemia (CML) Ph+. Preliminary Report of Mexican Cooperative Leukemia Group (GRUMELA).

Rafael Hurtado Monroy, MD, Pablo Vargas-Viveros, MD, Eduardo Cervera, MD, Myrna Candelaria, MD, Alvaro Aguayo, MD, Emma Gallardo, MD, Eucario Leon, MD, Juan Labardini, MD, Ricardo Sosa, MD, Rogelio Paredes, MD, Fernando Romero, MD, Oscar Perez, MD, Omar Coronel-Ayala, MD
Journal: Blood
Blood (2004) 104 (11): 1015.
https://doi.org/10.1182/blood.V104.11.1015.1015
Published: 2004